CureDuchenne
3334 East Coast Hwy 157
Corona del Mar
California
92625
United States
Tel: 949-721-4063
Fax: 949-760-1030
Website: http://www.cureduchenne.org/
Email: help@cureduchenne.org
72 articles about CureDuchenne
-
The recently launched company shared two posters at the Muscular Dystrophy Association’s annual conference this week ahead of a March 21 PDUFA date.
-
CureDuchenne Announces Educational Events for Families and Caregivers of Individuals with Duchenne or Becker Muscular Dystrophy
1/23/2024
CureDuchenne has announced its schedule of CureDuchenne Cares workshops and dinner sessions for the first half of the year, as well as its annual conference.
-
CureDuchenne Launches the CureDuchenne Caregiver Course: A Free Virtual Resource for Duchenne Muscular Dystrophy Caregivers
9/19/2023
CureDuchenne, a leading nonprofit organization dedicated to advancing research and improving the lives of individuals affected by Duchenne muscular dystrophy, is proud to announce the launch of the CureDuchenne Caregiver Course.
-
CureDuchenne, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy Announce Collaborative Project to Focus on Re-Dosing Gene Therapy in Duchenne Muscular Dystrophy
6/15/2023
CureDuchenne, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy, announced a collaborative clinical trial grant to test repurposing of the FDA-approved drug Vyvgart, for its potential ability to reduce antibodies to adeno-associated virus in Duchenne muscular dystrophy patients.
-
CureDuchenne Ventures Invests in MyoGene Bio and its AAV-Delivered CRISPR/Cas9 Gene Editing Approach
5/11/2023
CureDuchenne Ventures announced funding for MyoGene Bio, LLC, a biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy.
-
Global Nonprofit CureDuchenne to Host FUTURES National Conference for the Duchenne Muscular Dystrophy Community on April 20-23 in San Diego
3/9/2023
CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, announced its FUTURES National Conference will be held from April 20-23, 2023 in San Diego, California.
-
First CureDuchenne Clinic Opens in Greater Dallas Area to Provide Specialized Care for Underserved Duchenne Muscular Dystrophy Patients
3/3/2023
CureDuchenne announced the opening of The CureDuchenne Clinic, providing dedicated care and services to underserved and uninsured individuals with Duchenne and Becker muscular dystrophy.
-
CureDuchenne Launches Occupational Therapist Certification Program to Improve Care for Individuals with Duchenne Muscular Dystrophy
10/11/2022
CureDuchenne, a global leader in research, patient care and innovation for improving and extending the lives of those with Duchenne muscular dystrophy, launched the CureDuchenne Occupational Therapist Certification Program.
-
CureDuchenne Hosts Conversation with Pfizer to Discuss Opening of First U.S. Sites in Phase 3 Trial of Investigational Gene Therapy for Ambulatory Patients with Duchenne Muscular Dystrophy
5/16/2022
CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy (DMD), today released a webinar on the upcoming opening of U.S. trial sites for Pfizer's CIFFREO trial, a phase 3 study in ambulatory boys with DMD to assess the safety and efficacy of an investigational mini-dystrophin gene therapy.
-
Cureduchenne Strengthens Research and Investment Team With Addition of Vice President of Research and Partner of CureDuchenne Ventures
5/13/2022
CureDuchenne announced the promotion of Lianna Orlando, PhD, to Vice President of Research and the addition of Bradley Hodges, PhD as Partner of CureDuchenne Ventures.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Companies like Chameleon Biosciences and Code Biotherapeutics will present their latest research at the FUTURES 2022 conference hosted by CureDuchenne.
-
CureDuchenne Commits $1 Million to Gennao Bio to Accelerate Duchenne Muscular Dystrophy and Rare Muscle Disease Research
12/23/2021
CureDuchenne Ventures announces a $1 million investment in Gennao Bio's Series A extension to help the company apply their gene monoclonal antibody (GMAB) platform technology to Duchenne muscular dystrophy (DMD) and other rare muscle diseases.
-
CureDuchenne's National "FUTURES" Conference To Be Conducted Virtually October 8-10, Providing Expanded Access For The Duchenne Community
9/28/2021
CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces the annual FUTURES National Conference from October 8-10, 2021 will be hosted virtually this year.
-
NCGM, A Neuberg Diagnostics Company, Supports Implementation of Duchenne Muscular Dystrophy Supplementary Newborn Screening at a Boston Hospital
8/6/2021
On Aug 06 , both CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, and Brigham and Women's Hospital announced the first Duchenne muscular dystrophy (DMD), hospital-based testing program.
-
Cureduchenne Launches Next-generation Data-sharing Platform To Accelerate A Cure For Duchenne And Becker Muscular Dystrophy
6/18/2021
CureDuchenne announces the launch of CureDuchenne Link , a centralized data hub that puts individuals with Duchenne and Becker firmly at the center of research.
-
The CureDuchenne Futures National Conference For The Duchenne Community Returns In Fall 2021
5/26/2021
Registration Now Open for Duchenne Community Reunion, a Three-Day National Conference Taking Place in Texas Welcoming Attendees From Across the Globe
-
DuchenneXchange Launches V2.0 As Rare Disease Community Seeks "Safe" Place To Discuss Treatment, Research, COVID-19 Immunization And Other Critical Topics
4/6/2021
The volatility of the past year has created additional strain on families grappling with Duchenne muscular dystrophy, a severe X-linked form of muscular dystrophy that affects approximately 1 in 3,500 to 5,000 males born each year.
-
CureDuchenne Hosts Webinar on COVID-19 Vaccines to Educate Duchenne Community, Alongside Clinical, Scientific and Regulatory Experts
3/19/2021
CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a webinar to continue educating the Duchenne community about the COVID-19 vaccines.
-
CureDuchenne Congratulates Pfizer on Dosing First Patient in Phase III Clinical Trial for Duchenne Muscular Dystrophy
1/8/2021
CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), celebrates Pfizer Inc’s (NYSE: PFE) announcement surrounding the first dosing of a patient with Duchenne in their Phase III gene therapy clinical trial. Pfizer has showcased tremendous progress over the past year in pushing forward PF-06939926, its rAAV9 mini-dystrophin gene therapy for DMD. P